Abstract
Nociceptinergic system has become an important target for drug development since the identification of the “orphan”, opioid-like-1 receptor and the isolation of its endogenous agonist nociceptin. Involvement of nociceptinergic system has been verified in a wide range of pathophysiological processes. A large number of nociceptinergic agonists and antagonists with peptide and non-peptide structures have been developed. Several non-peptide nociceptinergic antagonists have recently shown effective on different animal models of parkinsonism. Neuropharmacological background for antiparkinsonian effect of nociceptinergic antagonists, experimental models with high predictive value, nociceptinergic antagonists shown to have potential effect in Parkinson’s disease are summarized. Medicinal chemistry data (logP and TPSA) of the NOP receptor antagonists which are found to be effective in animal models of Parkinson’s disease are provided.
Keywords: Animal models of Parkinson’s disease, antiparkinsonian effect, medicinal chemistry data, NOP receptor antagonists, logP, TPSA.
Mini-Reviews in Medicinal Chemistry
Title:Nociceptinergic System as Potential Target in Parkinson’s Disease
Volume: 13 Issue: 10
Author(s): Kornelia Tekes, Saeed Tariq, Ernest Adeghate, Rudolf Laufer, Farzad Hashemi, Afshan Siddiq and Huba Kalasz
Affiliation:
Keywords: Animal models of Parkinson’s disease, antiparkinsonian effect, medicinal chemistry data, NOP receptor antagonists, logP, TPSA.
Abstract: Nociceptinergic system has become an important target for drug development since the identification of the “orphan”, opioid-like-1 receptor and the isolation of its endogenous agonist nociceptin. Involvement of nociceptinergic system has been verified in a wide range of pathophysiological processes. A large number of nociceptinergic agonists and antagonists with peptide and non-peptide structures have been developed. Several non-peptide nociceptinergic antagonists have recently shown effective on different animal models of parkinsonism. Neuropharmacological background for antiparkinsonian effect of nociceptinergic antagonists, experimental models with high predictive value, nociceptinergic antagonists shown to have potential effect in Parkinson’s disease are summarized. Medicinal chemistry data (logP and TPSA) of the NOP receptor antagonists which are found to be effective in animal models of Parkinson’s disease are provided.
Export Options
About this article
Cite this article as:
Tekes Kornelia, Tariq Saeed, Adeghate Ernest, Laufer Rudolf, Hashemi Farzad, Siddiq Afshan and Kalasz Huba, Nociceptinergic System as Potential Target in Parkinson’s Disease, Mini-Reviews in Medicinal Chemistry 2013; 13 (10) . https://dx.doi.org/10.2174/13895575113139990006
DOI https://dx.doi.org/10.2174/13895575113139990006 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Large Bending Deformation of a Cantilevered Soft Beam under External Load: The Applicability of Inextensibility Assumption of the Centerline
Current Mechanics and Advanced Materials Antiplatelet Treatment in Ischemic Stroke Treatment
Current Topics in Medicinal Chemistry Neuro-psychopharmacogenetics and Neurological Antecedents of Posttraumatic Stress Disorder: Unlocking the Mysteries of Resilience and Vulnerability
Current Neuropharmacology GABAA Receptor Channel Pharmacology
Current Pharmaceutical Design A Systematic, Updated Review on the Antidepressant Agomelatine Focusing on its Melatonergic Modulation
Current Neuropharmacology Neurokinin-1 Receptor Antagonists in Lung Cancer Therapy
Letters in Drug Design & Discovery Vasopressin in Health and Disease with a Focus on Affective Disorders
Central Nervous System Agents in Medicinal Chemistry CD26/Dipeptidyl Peptidase IV as a Novel Therapeutic Target for Cancer and Immune Disorders
Mini-Reviews in Medicinal Chemistry Solution NMR Studies of Aβ Monomer Dynamics
Protein & Peptide Letters Transient Tachypnea of the Newborn: The Treatment Strategies
Current Pharmaceutical Design Effective Treatment of Human Lung Cancer by Targeting Tissue Factor with a Factor VII-Targeted Photodynamic Therapy
Current Cancer Drug Targets Intracellular Fate of Peptide-Mediated Delivered Cargoes
Current Pharmaceutical Design Layer Protecting the Surface of Zirconium Used in Nuclear Reactors
Recent Patents on Nanotechnology EMT Blockage Strategies: Targeting Akt Dependent Mechanisms for Breast Cancer Metastatic Behaviour Modulation
Current Gene Therapy Control of Copper Status for Cancer Therapy
Current Cancer Drug Targets Mucoadhesive Polymers for Oral Transmucosal Drug Delivery: A Review
Current Pharmaceutical Design The Growth Hormone Secretagogue Receptor (Ghs-R)
Current Pharmaceutical Design Anesthetic Considerations for Electroconvulsive Therapy-Especially Hemodynamic and Respiratory Management
Current Psychiatry Reviews Functions of S100 Proteins
Current Molecular Medicine Retinal Nerve Fiber Layer Thickness is Associated with Episodic Memory Deficit in Mild Cognitive Impairment Patients
Current Alzheimer Research